Decheng Capital LLC Cuts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Decheng Capital LLC cut its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 91.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,495 shares of the company’s stock after selling 45,272 shares during the period. Vera Therapeutics comprises about 0.0% of Decheng Capital LLC’s portfolio, making the stock its 26th biggest position. Decheng Capital LLC’s holdings in Vera Therapeutics were worth $108,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Huntington National Bank acquired a new position in shares of Vera Therapeutics during the fourth quarter worth about $26,000. GF Fund Management CO. LTD. acquired a new position in shares of Vera Therapeutics during the fourth quarter worth about $56,000. Summit Investment Advisors Inc. grew its position in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock worth $196,000 after buying an additional 639 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Vera Therapeutics by 1,779.1% during the first quarter. GAMMA Investing LLC now owns 8,287 shares of the company’s stock worth $199,000 after buying an additional 7,846 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Vera Therapeutics by 19.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company’s stock worth $229,000 after buying an additional 1,572 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on VERA. Guggenheim reissued a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Scotiabank reaffirmed an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Cantor Fitzgerald lowered their price target on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating for the company in a report on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price target (up from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Finally, Wedbush lowered their price target on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $65.00.

Insider Buying and Selling at Vera Therapeutics

In other news, Director Patrick G. Enright acquired 40,607 shares of the firm’s stock in a transaction dated Tuesday, June 24th. The stock was acquired at an average cost of $22.35 per share, with a total value of $907,566.45. Following the completion of the acquisition, the director owned 3,596,593 shares of the company’s stock, valued at $80,383,853.55. The trade was a 1.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 16.30% of the company’s stock.

Vera Therapeutics Price Performance

VERA stock opened at $20.72 on Wednesday. The company has a market capitalization of $1.32 billion, a P/E ratio of -6.91 and a beta of 1.19. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The business has a 50 day simple moving average of $22.84 and a 200-day simple moving average of $25.83. The company has a current ratio of 27.68, a quick ratio of 27.68 and a debt-to-equity ratio of 0.10.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter last year, the business earned ($0.56) earnings per share. As a group, equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.